ABMAX Biotechnology (Beijing) Co., Ltd. was established in 2006 and is a national high-tech enterprise. The company owns one of the world's most advanced one-stop antibody and kit development technology platform. The average time for monoclonal antibody development is only 46 days, with a success rate as high as 90%, making it the fastest, best, and most competitive antibody development service provider in the world. The company has also awarded many national and Beijing municipal scientific and technological research grants, maintains in-depth and extensive collaborations with well-known domestic and international research institutions and enterprises, and has established a quality management system in compliance with GLP standards.

In 2012, the company began promoting the development services of vaccine component-specific mouse monoclonal antibodies and vaccine antigen quantitative detection kits. To date, it has served nearly a hundred domestic and international vaccine companies and helped several vaccine products complete non-clinical or clinical studies as vaccine quality control reagents, including rabies vaccines, multivalent HPV vaccines, pertussis vaccines, and pneumonia vaccines.

In 2016, ABMAX took the lead in developing immunogenicity assays for biological drugs in accordance with the new US FDA guidelines, while also establishing a drug PK assay development platform and expanding the generations of monoclonal and polyclonal anti-drug antibodies (ADA). Relying on its antibody reagent and methodology development technology platform in the field of biopharmaceutical testing, ABMAX has led the development of this niche market segment. Currently, in generations of anti-drug antibodies, ABMAX has achieved a market share of around 50% in the northern region and over 30% in the southern region of China.

In January 2020, the company independently undertook and successfully completed one of the first five COVID-19 projects of the Beijing Municipal Science and Technology Commission, receiving a grant of 2 million yuan. In the same month, it obtained a US$100,000 grant from the BM Gates Foundation to conduct research and development of COVID-19 antibodies.

In March 2020, ABMAX Biotechnology (Tianjin) Co., Ltd. was established and located in the International Joint Academy of Biomedicine in Tianjin Binhai New Area, receiving a special anti-COVID-19 epidemic fund of 3 million yuan from the Tianjin Economic-Technological Development Area. The company leases an area of 1,100 square meters, with 800 square meters dedicated to the experimental base. Building on the foundation of antibody development and methodology development from its Beijing parent company, Tianjin ABMAX has established a research, development, and production base for kit products.

In the second half of 2023, ABMAX began to shift its core business from CRO services to critical reagents for quality control of biological drugs and vaccines. Based on the company's global most comprehensive library of infectious disease pathogen monoclonal antibodies, it cooperated with regulatory authorities and multiple vaccine companies to jointly develop standardized antibody products and detection kits for vaccine quality control. These include antigen quantification and in vitro potency assays for pneumococcal polysaccharide vaccines, HPV vaccines, rabies vaccines, pertussis vaccines, and shingles vaccines, most of which are unique with IP protection.

The company has a total of 36 employees, including 22 researchers and a sales team of 4. There are 3 employees with doctoral degrees, 8 with master's degrees, and 11 with bachelor's degrees.